

REMARKS

This paper is being provided in response to the Final Office Action dated September 20, 2005, for the above-referenced application. In this response, Applicant has made minor modifications to the specification and cancelled claims 1, 13, 14 and 18-20. Applicant respectfully submits that the amendments to the specification do not add new matter.


Applicant gratefully acknowledges the allowance of claims 2-12 and 15-17.

The objection to the specification has been addressed by amendments to the specification provided herein in accordance with the guidelines set forth in the Office Action. Accordingly, Applicant respectfully requests that this objection be withdrawn.

The rejection of claims 1, 13, 14 and 18-20 under 35 U.S.C. 102(b) as being anticipated by U.S. Patent No. 5,397,931 to Bayer (hereinafter "Bayer") has been made moot by cancellation of those claims herein.

Based on the above, Applicants respectfully request that the Examiner reconsider and withdraw all outstanding rejections and objections. Favorable consideration and allowance are earnestly solicited. Should there be any questions after reviewing this paper, the Examiner is invited to contact the undersigned at 508-898-8603.

Respectfully submitted,
MUIRHEAD AND SATURNELLI, LLC



Donald W. Muirhead
Registration No. 33,978

Date: December 19, 2005

Muirhead and Saturnelli, LLC
200 Friberg Parkway, Suite 1001
Westborough, MA 01581
Phone: (508) 898-8601
Fax: (508) 898-8602